泰格医药2025年净利同比预增105%至204%

Core Viewpoint - Tiger Med (300347) forecasts a net profit attributable to shareholders for 2025 to be between 830 million and 1.23 billion yuan, representing a year-on-year growth of 105% to 204% [1] Group 1: Financial Performance - The company expects significant improvement in investment income and fair value changes from non-current financial assets, which include investments in non-listed companies, listed company shares, and pharmaceutical funds [1] - The anticipated net new orders for 2025 are projected to be between 9.5 billion and 10.5 billion yuan, compared to 8.42 billion yuan in the same period of 2024 [1] Group 2: Industry Context - The recovery of China's innovative pharmaceutical industry is expected to lead to a noticeable increase in the value of innovative assets within the sector [1]